Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis

COMMENTED

Rheumatoid Arthritis

Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials

Clin Rheumatol.

Kunwar S, Collins CE, Constantinescu F

doi: 10.1007/s10067-018-4199-7.

Rheumatoid Arthritis

Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic DMARDs in the treatment of moderate-to-severe rheumatoid arthritis.

Arthritis Rheumatol.

Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, Shay K, Wang X, Garg JP, Cardiel MH

doi: 10.1002/art.40054.

Rheumatoid Arthritis

Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors

Expert Rev Clin Immunol.

Atzeni F, Talotta R, Nucera V, Marino F, Gerratana E, Sangari D, Masala IF, Sarzi-Puttini P

doi: 10.1080/1744666X.

Rheumatoid Arthritis

The effect of treatments for rheumatoid arthritis on endothelial dysfunction evaluated by flow-mediated vasodilation in patients with rheumatoid arthritis

Curr Vasc Pharmacol.

Kotani K, Miyamoto M, Ando H

Rheumatoid Arthritis

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

Rheumatology (Oxford).

Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, Winthrop KL, Galloway JB

doi: 10.1093/rheumatology/

Rheumatoid Arthritis

High Serum Interleukin-6 is Associated With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab from Adalimumab or Methotrexate in a Post Hoc Analysis

Arthritis Rheumatol.

Boyapati A, Schwartzman S, Msihid J, Choy E, Genovese MC, Burmester GR, Lam G, Kimura T, Sadeh J, Weinreich DM, Yancopoulos GD, Graham NMH

doi: 10.1002/art.41299.

Rheumatoid Arthritis

Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis

Arthritis Res Ther.

Smolen JS, Kang YM, Yoo WH, Emery P, Weinblatt ME, Keystone EC, Genovese MC, Myung G, Baek I, Ghil J

doi: 10.1186/s13075-020-02267-z.

Rheumatoid Arthritis

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate

Ann Rheum Dis.

Smolen JS, van Vollenhoven RF, Florentinus S, Chen S, Suboticki JL, Kavanaugh A

doi: 10.1136/annrheumdis-2018-213502.

Melanoma and Skin CancerRheumatoid Arthritis

Baricitinib, Methotrexate, or Combination in Patients with Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment

Arthritis Rheumatol.

Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S, Dickson C, de Bono S, Schlichting D, Beattie S, Kuo WL, Rooney T, Macias W, Takeuchi T

doi: 10.1002/art.39953.

Related content

Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials

Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic DMARDs in the treatment of moderate-to-severe rheumatoid arthritis.

Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors

The effect of treatments for rheumatoid arthritis on endothelial dysfunction evaluated by flow-mediated vasodilation in patients with rheumatoid arthritis

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

High Serum Interleukin-6 is Associated With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab from Adalimumab or Methotrexate in a Post Hoc Analysis

Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate

Baricitinib, Methotrexate, or Combination in Patients with Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment